Penumbra price target raised to $325 from $285 at Truist

Truist raised the firm’s price target on Penumbra (PEN) to $325 from $285 and keeps a Buy rating on the shares. The company’s top-line driven beat was driven by U.S. Thrombectomy upside, which grew about 27% and was well-ahead of consensus, while gross and operating margin upside drove an 8% EPS beat, the analyst tells investors in a research note. Penumbra is a rare, profitable, $1B double-digit revenue grower with sustained 15%-20% out-year revenue growth prospects, the firm adds.